Andre Birgy

Dr. Andre Birgy


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2022 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
CHClaire Amaris Hobson
Claire Amaris Hobson
GPGautier Pierrat
Gautier Pierrat
OTOlivier Tenaillon
Olivier Tenaillon
SBStéphane Bonacorsi
Stéphane Bonacorsi
BBBéatrice Bercot
Béatrice Bercot
ABAndre Birgy
Andre Birgy
First variants of the Klebsiella pneumoniae carbapenemase (KPC), KPC-2 and KPC-3, have encountered a worldwide success, particularly in K. pneumoniae isolates. These beta-lactamases conferred resistance to most beta-lactams including carbapenems but remained susceptible to new beta-lactam/beta-lactamase inhibitors, such as ceftazidime-avibactam.

1 August 2021 in Clinical Microbiology and Infection
Verified
Journal Article
Open access
CHClaire Amaris Hobson
Claire Amaris Hobson
ACAurélie Cointe
Aurélie Cointe
HJHervé Jacquier
Hervé Jacquier
ACAlaksh Choudhury
Alaksh Choudhury
MMMélanie Magnan
Mélanie Magnan
ABAndre Birgy
Andre Birgy
Ceftazidime-avibactam and cefiderocol are recently commercialized molecules active against highly drug-resistant bacteria, including carbapenem-resistant Enterobacteriaceae. Resistant mutants to ceftazidime-avibactam were described and notably in Klebsiella pneumoniae carbapenemase (KPC). Considering the structural similarities between ceftazidime and cefiderocol, we hypothesized that resistance to ceftazidime-avibactam in KPC-producing Enterobacterales may lead to cross-resistance to cefiderocol. Ceftazidime-avibactam resistant mutants from 3 clinical isolates of Enterobacterales carrying either blaKPC-2 or blaKPC-3 were selected in vitro. Mutants with increased MIC to ceftazidime-avibactam compared to ancestral allele were cloned in pBR322 plasmid and expressed in E. coli TOP10. We evaluated the impact of these mutations on cefiderocol MICs, MBCs and assessed the impact of bacterial inoculum on cefiderocol MICs. We used 37 KPC mutants with increased ceftazidime-avibactam MIC. Of these, 6 were previously described in clinical isolates. Compared to the wild-type alleles, 4 to 32-fold-increase in the cefiderocol's MICs were observed for 75.6% (28/37) of tested mutants, reaching MIC up to 4 mg/L in E. coli TOP10 for KPC-31 (D179Y-H274Y mutations). MBCs and MICs of cefiderocol were similar, confirming the bactericidal activity of this drug. Finally, when using higher inocula (107 CFU/ml), a high increase in cefiderocol MIC was observed and all isolates were categorized as resistant. We observed that most of the CZA resistant KPC variants have a possible impact on cefiderocol by increasing the cefiderocol MICs. In addition, cefiderocol is greatly impacted by inoculum effect, suggesting precautions should be taken when treating infections with a suspected high inoculum.

1 February 2019 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
CHClaire Amaris Hobson
Claire Amaris Hobson
SBStéphane Bonacorsi
Stéphane Bonacorsi
MFMony Fahd
Mony Fahd
ABAndré Baruchel
André Baruchel
ACAurélie Cointe
Aurélie Cointe
ABAndre Birgy
Andre Birgy
Worldwide spread of multiresistant bacteria, especially carbapenemase-producing Enterobacteriaceae, can lead to situations for which no antibiotic therapy option is available.…

17 November 2020 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
CHClaire Amaris Hobson
Claire Amaris Hobson
SBStéphane Bonacorsi
Stéphane Bonacorsi
HJHervé Jacquier
Hervé Jacquier
ACAlaksh Choudhury
Alaksh Choudhury
MMMélanie Magnan
Mélanie Magnan
ABAndre Birgy
Andre Birgy
To explore the mutational possibilities of insertions and deletions (indels) in the Klebsiella pneumoniae carbapenemase (KPC) beta-lactamase, we selected for ceftazidime-avibactam-resistant mutants. Of 96 screened mutants, we obtained 19 indels (2 to 15 amino acids), all located in the loops surrounding the active site. Three antibiotic susceptibility phenotypes emerged: an extended-spectrum-beta-lactamase-like phenotype, an activity restricted to ceftazidime, and a carbapenem-susceptible KPC-like phenotype.

6 March 2024 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
ABAndre Birgy
Andre Birgy
CNChristina Nnabuife
Christina Nnabuife
TPTimothy Palzkill
Timothy Palzkill
Klebsiella pneumoniae carbapenemase (KPC) variants have been described that confer resistance to both ceftazidime–avibactam and cefiderocol. Of these, KPC-33 and KPC-31 are D179Y-containing variants derived from KPC-2 and KPC-3, respectively. To better understand this atypical phenotype, the catalytic mechanism of ceftazidime and cefiderocol hydrolysis by KPC-33 and KPC-31 as well as the ancestral KPC-2 and KPC-3 enzymes was studied. Steady-state kinetics showed that the D179Y substitution in either KPC-2 or KPC-3 is associated with a large decrease in both k cat and K M such that k cat / K M values were largely unchanged for both ceftazidime and cefiderocol substrates. A decrease in both k cat and K M is consistent with a decreased and rate-limiting deacylation step. We explored this hypothesis by performing pre-steady-state kinetics and showed that the acylation step is rate-limiting for KPC-2 and KPC-3 for both ceftazidime and cefiderocol hydrolysis. In contrast, we observed a burst of acyl-enzyme formation followed by a slow steady-state rate for the D179Y variants of KPC-2 and KPC-3 with either ceftazidime or cefiderocol, indicating that deacylation of the covalent intermediate is the rate-limiting step for catalysis. Finally, we show that the low K M value for ceftazidime or cefiderocol hydrolysis of the D179Y variants is not an indication of tight binding affinity for the substrates but rather is a reflection of the deacylation reaction becoming rate-limiting. Thus, the hydrolysis mechanism of ceftazidime and cefiderocol by the D179Y variants is very similar and involves the formation of a long-lived covalent intermediate that is associated with resistance to the drugs.

1 December 2018 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
ACAurélie Cointe
Aurélie Cointe
SBStéphane Bonacorsi
Stéphane Bonacorsi
JTJeanne Truong
Jeanne Truong
CHClaire Hobson
Claire Hobson
CDCatherine Doit
Catherine Doit
ABAndre Birgy
Andre Birgy
We evaluated the performance of the RESIST-4 O.K.N.V. assay (Coris) with 98 isolates to detect OXA-48-like and KPC-, NDM-, and VIM-type carbapenemases directly on positive human blood cultures.